246 related articles for article (PubMed ID: 29494632)
41. Highly sensitive ratiometric detection of heparin and its oversulfated chondroitin sulfate contaminant by fluorescent peptidyl probe.
Mehta PK; Lee H; Lee KH
Biosens Bioelectron; 2017 May; 91():545-552. PubMed ID: 28086125
[TBL] [Abstract][Full Text] [Related]
42. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
Bairstow S; McKee J; Nordhaus M; Johnson R
Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
[TBL] [Abstract][Full Text] [Related]
43. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
[TBL] [Abstract][Full Text] [Related]
44. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
45. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
[TBL] [Abstract][Full Text] [Related]
46. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
Alban S; Lühn S; Schiemann S
Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
[TBL] [Abstract][Full Text] [Related]
47. Influence of the oversulfation method and the degree of sulfation on the anticoagulant properties of dermatan sulfate derivatives.
Maaroufi RM; Tapon-Bretaudiere J; Mardiguian J; Sternberg C; Dautzenberg MD; Fischer AM
Thromb Res; 1990 Aug; 59(4):749-58. PubMed ID: 2080493
[TBL] [Abstract][Full Text] [Related]
48. The anticoagulant properties of mast cell product, chondroitin sulphate E.
Scully MF; Ellis V; Seno N; Kakkar VV
Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
[TBL] [Abstract][Full Text] [Related]
49. Distinct structures of the α-fucose branches in fucosylated chondroitin sulfates do not affect their anticoagulant activity.
Santos GR; Glauser BF; Parreiras LA; Vilanova E; Mourão PA
Glycobiology; 2015 Oct; 25(10):1043-52. PubMed ID: 26092839
[TBL] [Abstract][Full Text] [Related]
50. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
[TBL] [Abstract][Full Text] [Related]
51. Simple fluorescence assay for quantification of OSCS in heparin.
Lühn S; Schiemann S; Alban S
Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
[TBL] [Abstract][Full Text] [Related]
52. Characterization and anticoagulant activity of a fucosylated chondroitin sulfate with unusually procoagulant effect from sea cucumber.
Ben Mansour M; Balti R; Ollivier V; Ben Jannet H; Chaubet F; Maaroufi RM
Carbohydr Polym; 2017 Oct; 174():760-771. PubMed ID: 28821129
[TBL] [Abstract][Full Text] [Related]
53. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events.
Guerrini M; Beccati D; Shriver Z; Naggi A; Viswanathan K; Bisio A; Capila I; Lansing JC; Guglieri S; Fraser B; Al-Hakim A; Gunay NS; Zhang Z; Robinson L; Buhse L; Nasr M; Woodcock J; Langer R; Venkataraman G; Linhardt RJ; Casu B; Torri G; Sasisekharan R
Nat Biotechnol; 2008 Jun; 26(6):669-75. PubMed ID: 18437154
[TBL] [Abstract][Full Text] [Related]
54. Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation.
Yi Qian ; Jing Pan ; Xiaodong Zhou ; Hourcade DE; Liszewski MK; Atkinson JP; Hong Lu ; Lijuan Zhang
Clin Appl Thromb Hemost; 2010 Jun; 16(3):244-50. PubMed ID: 20547553
[TBL] [Abstract][Full Text] [Related]
55. Preparation, characterization and anticoagulant activity in vitro of heparin-like 6-carboxylchitin derivative.
Yang J; Cai J; Wu K; Li D; Hu Y; Li G; Du Y
Int J Biol Macromol; 2012 May; 50(4):1158-64. PubMed ID: 22266383
[TBL] [Abstract][Full Text] [Related]
56. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data.
Zang Q; Keire DA; Buhse LF; Wood RD; Mital DP; Haque S; Srinivasan S; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
Anal Bioanal Chem; 2011 Aug; 401(3):939-55. PubMed ID: 21678118
[TBL] [Abstract][Full Text] [Related]
57. Modulation of vascular human endothelial and rat smooth muscle cell growth by a fucosylated chondroitin sulfate from echinoderm.
Tapon-Bretaudière J; Drouet B; Matou S; Mourão PA; Bros A; Letourneur D; Fischer AM
Thromb Haemost; 2000 Aug; 84(2):332-7. PubMed ID: 10959709
[TBL] [Abstract][Full Text] [Related]
58. Development and validation of an ion-exchange chromatography method for heparin and its impurities in heparin products.
Thiangthum S; Vander Heyden Y; Buchberger W; Viaene J; Prutthiwanasan B; Suntornsuk L
J Sep Sci; 2014 Nov; 37(22):3195-204. PubMed ID: 25146711
[TBL] [Abstract][Full Text] [Related]
59. One-hour screening of adulterated heparin by simplified peroxide digestion and fast RPIP-LC-MS(2).
Li H; Wickramasekara S; Nemes P
Anal Chem; 2015 Aug; 87(16):8424-32. PubMed ID: 26168275
[TBL] [Abstract][Full Text] [Related]
60. Sensitive detection of oversulfated chondroitin sulfate in heparin sodium or crude heparin with a colorimetric microplate based assay.
Sommers CD; Mans DJ; Mecker LC; Keire DA
Anal Chem; 2011 May; 83(9):3422-30. PubMed ID: 21449571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
